Table 1.

Pharmacokinetic Properties of Fused Hirudin and RSA

HLAH6RSA
jT .151 ± .009 .125 ± .002 
j3 .792 ± .019 .314 ± .001 
j3.5 .436 ± .055 .248 ± .018 
Ap .191 ± .008 .399 ± .007 
Aw .160 ± .053 .109 ± .035 
Ae .649 ± .061 .532 ± .024 
HLAH6RSA
jT .151 ± .009 .125 ± .002 
j3 .792 ± .019 .314 ± .001 
j3.5 .436 ± .055 .248 ± .018 
Ap .191 ± .008 .399 ± .007 
Aw .160 ± .053 .109 ± .035 
Ae .649 ± .061 .532 ± .024 

Comparison of fractional catabolic rates and compartmental distributions of HLA(H)6 (this study, see Fig 8) and of RSA.36 Symbols: jT , j3 , and j3.5 , fractions of fusion protein or RSA in total body, plasma compartment, and plasma compartment plus noncirculating vessel wall catabolized per day; Ap , Aw , and Ae , fractions of total body fusion protein or RSA in plasma, noncirculating vessel wall, and extravascular compartments, respectively. Data were calculated from individual plasma curves as described in Materials and Methods.

or Create an Account

Close Modal
Close Modal